How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/sedation-as-adjunct-to-anesthesia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sedation as Adjunct to Anesthesia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sedation as Adjunct to Anesthesia (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Sedation as Adjunct to Anesthesia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Diprivan	Propofol	Fresenius Kabi	General anesthetic	GABA A receptors	1989-01-01
Versed	midazolam	Generic (originally Roche)	Benzodiazepine (short-acting)	Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2	1985-12-20
Versed	Midazolam Hydrochloride	Takeda Pharmaceutical Company Limited	Benzodiazepine	GABA A receptor alpha-5/beta-2/gamma-2	1985-01-01
Ativan	lorazepam	Generic (originally Wyeth/Pfizer)	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver	1977-09-30
Meperidine Hydrochloride Preservative Free	Meperidine Hydrochloride	Pfizer	Opioid Agonist	Mu-type opioid receptor	1942-01-01
Pethidin	Pethidin	Ain Shams University		Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor
Diprivan	Diprivan	St. Antonius Hospital		Cytochrome P450 2C9, Fatty-acid amide hydrolase 1, Transient receptor potential cation channel subfamily V member 4
Lusedra	Lusedra	Eisai Inc.		GABA-A receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Sedation as Adjunct to Anesthesia
Ain Shams University · 1 drug in Sedation as Adjunct to Anesthesia
Eisai Inc. · 1 drug in Sedation as Adjunct to Anesthesia
Fresenius Kabi · 1 drug in Sedation as Adjunct to Anesthesia
Generic (originally Roche) · 1 drug in Sedation as Adjunct to Anesthesia
Generic (originally Wyeth/Pfizer) · 1 drug in Sedation as Adjunct to Anesthesia
Pfizer · 1 drug in Sedation as Adjunct to Anesthesia
St. Antonius Hospital · 1 drug in Sedation as Adjunct to Anesthesia
Takeda Pharmaceutical Company Limited · 1 drug in Sedation as Adjunct to Anesthesia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sedation as Adjunct to Anesthesia:

Cite this brief

Drug Landscape (2026). Sedation as Adjunct to Anesthesia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sedation-as-adjunct-to-anesthesia. Accessed 2026-06-10.

Sedation as Adjunct to Anesthesia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing